Marina Biotech this week said that a nine-month non-human primate toxicology study of its familial adenomatous polyposis treatment CEQ508 has shown the drug to be safe after repeated administration.

In the study, 18 cynomolgus monkeys received daily oral doses of either CEQ508 or a control agent for 281 days. No drug-related adverse responses were found in regards to clinical observation, body weights and temperatures, serum chemistry, coagulation, hematology, urinalysis, cytokines, or gross pathology, Marina said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.